• FDA Grants Priority Review to Capmatinib in METex14+ NSCLC

    • February 12, 2020
    • Posted By : Peeyush Jaiswal
    • 0 Comment

    The FDA approved and granted a priority review to the new drug application (NDA) for capmatinib (INC280), according to Novartis, the drug’s developer.

    The MET inhibitor, capmatinib, is being analyzed as a potential first-line treatment for previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14)-mutated non-small cell lung cancer (NSCLC).

    As it stands, there are currently no approved therapies that target METex14-mutated advanced NSCLC, meaning if approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer.

    “We are extremely encouraged by the FDA’s priority review designation for capmatinib, a MET inhibitor that may be a major treatment advance for patients with this particularly aggressive form of lung cancer,” John Tsai, MD, head of global drug development and chief medical officer at Novartis, said in a news release.

    METex14 mutations occur in 3%-4% of newly diagnosed advanced NSCLC cases. 

    The NDA was supported by encouraging results from the GEOMETRY mono-1 phase II study in which the overall response rate was 67.9% (95% CI, 47.6-84.1) and 40.6% (95% CI, 28.9-53.1) among treatment-naïve and previously treated patients, respectively.


You Might Also Like

No comments found



error: Content is protected !!